Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Core Viewpoint - Candel Therapeutics, Inc. announced that an abstract for an oral presentation regarding its phase 3 clinical trial of CAN-2409 in localized prostate cancer has been accepted for the 2025 ASCO Annual Meeting, highlighting the company's focus on developing immunotherapies for cancer treatment [1]. Group 1: Clinical Trial and Presentation Details - The oral presentation will feature data from the phase 3 clinical trial of CAN-2409, targeting patients with intermediate-to-high risk localized prostate cancer [1]. - The session is scheduled for June 3, 2025, at the ASCO Annual Meeting in Chicago, IL, with Dr. Theodore DeWeese as the presenter [8]. Group 2: Product Information - CAN-2409 is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the HSV-tk gene to tumors, inducing a systemic immune response against cancer cells [5]. - The therapy has shown promising results in previous trials, including a significant improvement in disease-free survival when combined with standard radiation therapy in localized prostate cancer [6]. Group 3: Clinical Development and Regulatory Designations - Candel's clinical development program for CAN-2409 includes positive phase 2a trials in non-small cell lung cancer and pancreatic ductal adenocarcinoma, as well as a successful phase 3 trial in localized prostate cancer [6][9]. - The FDA has granted Fast Track Designation for CAN-2409 for multiple cancer types, including localized prostate cancer and PDAC, indicating its potential therapeutic significance [9].